Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
BMC Infectious Diseases
|
May 4, 2017
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam
Myra W Popejoy, Jianmin Long, Jennifer A Huntington
International Journal of Antimicrobial Agents
|
March 30, 2018
Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection
Alan J Xiao, Jennifer A Huntington, Jianmin Long, et al.
Journal of Clinical Pharmacology
|
June 23, 2015
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
Alan J Xiao, Benjamin W Miller, Jennifer A Huntington, et al.
The Journal of Antimicrobial Chemotherapy
|
July 10, 2012
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
Gurudatt Chandorkar, Jennifer A Huntington, Mark H Gotfried, et al.
Infectious Diseases and Therapy
|
December 26, 2016
PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease
Alan J Xiao, Luzelena Caro, Myra W Popejoy, et al.
BMC Infectious Diseases
|
June 14, 2012
Daptomycin therapy for osteomyelitis: a retrospective study
Jason C Gallagher, Jennifer A Huntington, Darren Culshaw, et al.
Clinical Pharmacology in Drug Development
|
March 9, 2018
Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo-Controlled, Multiple-Dose Study
Brian Yu, Adedayo Adedoyin, Ellie Hershberger, et al.
Antimicrobial Agents and Chemotherapy
|
December 15, 2020
Molecular Characterization of Baseline <i>Enterobacterales</i> and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial
Mariana Castanheira, Matthew G Johnson, Brian Yu, et al.
The Journal of Antimicrobial Chemotherapy
|
March 20, 2016
Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial
Jennifer A Huntington, George Sakoulas, Obiamiwe Umeh, et al.
Microbiology Spectrum
|
September 12, 2023
Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis
Emmanuel Roilides, John S Bradley, Julia Lonchar, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
BMC Infectious Diseases
|
May 4, 2017
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam
Myra W Popejoy, Jianmin Long, Jennifer A Huntington
International Journal of Antimicrobial Agents
|
March 30, 2018
Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection
Alan J Xiao, Jennifer A Huntington, Jianmin Long, et al.
Journal of Clinical Pharmacology
|
June 23, 2015
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
Alan J Xiao, Benjamin W Miller, Jennifer A Huntington, et al.
The Journal of Antimicrobial Chemotherapy
|
July 10, 2012
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
Gurudatt Chandorkar, Jennifer A Huntington, Mark H Gotfried, et al.
Infectious Diseases and Therapy
|
December 26, 2016
PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease
Alan J Xiao, Luzelena Caro, Myra W Popejoy, et al.
BMC Infectious Diseases
|
June 14, 2012
Daptomycin therapy for osteomyelitis: a retrospective study
Jason C Gallagher, Jennifer A Huntington, Darren Culshaw, et al.
Clinical Pharmacology in Drug Development
|
March 9, 2018
Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo-Controlled, Multiple-Dose Study
Brian Yu, Adedayo Adedoyin, Ellie Hershberger, et al.
Antimicrobial Agents and Chemotherapy
|
December 15, 2020
Molecular Characterization of Baseline <i>Enterobacterales</i> and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial
Mariana Castanheira, Matthew G Johnson, Brian Yu, et al.
The Journal of Antimicrobial Chemotherapy
|
March 20, 2016
Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial
Jennifer A Huntington, George Sakoulas, Obiamiwe Umeh, et al.
Microbiology Spectrum
|
September 12, 2023
Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis
Emmanuel Roilides, John S Bradley, Julia Lonchar, et al.
Page
of 3